New Label Expansion in Generalized Myasthenia Gravis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

  • By

  • Kathryn Wighton

  • May 11, 2026

  • 2 min

Share

  • 1

    The FDA expanded the indication for efgartigimod to include all adults with generalized myasthenia gravis, regardless of antibody status.

  • 2

    The approval encompasses patients who are AChR-Ab positive, MuSK-Ab positive, LRP4-Ab positive, and triple seronegative.

  • 3

    The Phase 3 ADAPT SERON trial demonstrated significant improvement in MG-ADL scores for patients treated with efgartigimod compared to placebo.

  • 4

    Efgartigimod showed a mean 3.35-point improvement in MG-ADL total score at week 4, with benefits observed across various antibody subgroups.

  • 5

    The treatment was well tolerated, with common side effects including respiratory infections, headaches, and injection-site reactions.

Original Source(s)

New Label Expansion in Generalized Myasthenia Gravis

  • by Kathryn Wighton

  • May 11, 2026

Related Content

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.

The drugs and devices have been on the market for years. But FDA-ordered studies still aren’t done.

“Doctors rely on this evidence, patients rely on this evidence, and if that evidence is not there, it’s going to lead to a lot of uncertainty."

FDA Clears Exoskeleton for Spinal Cord Injury

Use is limited to level indoor and adjoining outdoor areas and requires supervision by a companion with specialized training.